Repurposing a Diabetes Drug for Pulmonary Hypertension (1 of 3) (IMAGE)

American Association for the Advancement of Science (AAAS)

Repurposing a Diabetes Drug for Pulmonary Hypertension (1 of 3)

Caption

Photographs (A), CT scans (B), staining (C), and microscopic images (D) of hearts from four groups of rats used in the study. The first two groups were control groups (ConNx and ConHx). The third group was treated with a compound that induces right ventricle heart failure (SuHx), which was reversed in a fourth group with administration of pioglitazone (SuHx + Pio). This material relates to a paper that appeared in the 25 April, issue of Science Translational Medicine, published by AAAS. The paper, by E. Legchenko at Hannover Medical School in Hannover, Germany, and colleagues was titled, "PPAR? agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation."

Credit

E. Legchenko <i>et al., Science Translational Medicine</i> (2018)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.